|
| Reference population N = 694 |
| OADs alone One treatment Metformin Other Two treatments Metformin + DPP-4 inhibitor Metformin + Sulfonylurea Other Three treatments Metformin + Sulfonylurea + DPP-4 inhibitor Metformin + DPP-4 inhibitor + SGLT2 inhibitor Other Four treatments Metformin + Sulfonylurea + DPP-4 inhibitor + Thiazolidinediones Metformin + Sulfonylurea + DPP-4 inhibitor + SGLT2 Other | 510 (73.5%) 114 (22.4%) 100 (87.7%) 14 (12.3%) 216 (42.4%) 128 (59.3%) 67 (31.0%) 21 (9.7%) 151 (29.6%) 96 (63.58%) 21 (13.9%) 34 (22.5%) 29 (5.7%) 15 (51.7%) 12 (41.4%) 2 (6.9%) |
| Injectables alone One treatment Premixed insulin Basal insulin GLP-1 receptor agonist Two treatments Basal insulin + prandial insulin Basal insulin + premixed insulin | 28 (4.0%) 23 (82.1%) 19 (82.6%) 3 (13.0%) 1 (4.4%) 5 (17.9%) 3 (60.0%) 2 (40%) |
| OADs + injectables Two treatments Metformin + premixed insulin Metformin + basal insulin Metformin + GLP-1 receptor agonist Other Three treatments Metformin + DPP-4 inhibitor + basal insulin Metformin + DPP-4 inhibitor + premixed insulin Metformin + sulfonylurea + basal insulin Other Four or more treatments Metformin + DPP-4 inhibitor + sulfonylurea + basal insulin Metformin + DPP-4 inhibitor + sulfonylurea + premixed insulin Other | 156 (22.5%) 37 (23.7%) 17 (46.0%) 6 (16.2%) 6 (16.2%) 8 (21.6%) 64 (41.0%) 16 (25.0%) 12 (18.8%) 8 (12.5%) 28 (43.8%) 55 (35.3%) 18 (32.7%) 6 (10.9%) 31 (56.4%) |